Ardelyx
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 267
- Market Cap
- $1.4B
- Website
- http://www.ardelyx.com
- Introduction
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Clinical Trials
29
Trial Phases
4 Phases
Drug Approvals
5
Drug Approvals
Tenapanor Hydrochloride Tablets
- Product Name
- 万缇乐
- Approval Number
- 国药准字HJ20250022
- Approval Date
- Feb 20, 2025
Tenapanor Hydrochloride Tablets
- Product Name
- 万缇乐
- Approval Number
- 国药准字HJ20250020
- Approval Date
- Feb 20, 2025
Tenapanor Hydrochloride Tablets
- Product Name
- 万缇乐
- Approval Number
- 国药准字HJ20250021
- Approval Date
- Feb 20, 2025
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)• Click on a phase to view related trials
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
- Conditions
- Irritable Bowel Syndrome with Constipation (IBS-C)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 72
- Registration Number
- NCT06553547
- Locations
- 🇺🇸
Texas Digestive Specialists, Harlingen, Texas, United States
🇺🇸Florida Pharmaceutical Research and Associates, Inc., South Miami, Florida, United States
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 7
- Registration Number
- NCT06203444
- Locations
- 🇺🇸
DDSI, Oklahoma City, Oklahoma, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 150
- Registration Number
- NCT05905926
- Locations
- 🇺🇸
OSF Saint Francis Medical Center, Peoria, Illinois, United States
🇺🇸Maspons Pediatric Gastro, El Paso, Texas, United States
🇺🇸G & L Research, LLC, Foley, Alabama, United States
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
- Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Interventions
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 180
- Registration Number
- NCT05643534
- Locations
- 🇺🇸
Orlando Health, Inc.- APH Center for Digestive Health and Nutrition, Orlando, Florida, United States
🇺🇸OSF Saint Francis Medical Center, Peoria, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 109
- Registration Number
- NCT04780841
- Locations
- 🇺🇸
Horizon Research Group LLC, Coral Gables, Florida, United States
🇺🇸Panax Clinical Research LLC, Miami Lakes, Florida, United States
🇺🇸South Florida Research Phase I-IV; Inc., Miami Springs, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Avadel Pharmaceuticals Appoints Susan Rodriguez as Chief Operating Officer to Drive LUMRYZ Commercial Expansion
Avadel Pharmaceuticals has appointed Susan Rodriguez as Chief Operating Officer to lead commercial strategy and operations for LUMRYZ, the first once-at-bedtime oxybate treatment for narcolepsy.
China Approves First-in-Class Tenapanor for Hyperphosphatemia in Dialysis Patients
Fosun Pharma's Wan Ti Le (tenapanor hydrochloride tablets) has received NMPA approval for controlling serum phosphorus in dialysis patients with chronic kidney disease who have inadequate response to phosphate binders.